Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Sep 24;17(4):486–496. doi: 10.1016/j.bbmt.2010.09.015

The percent of CD4+ cells in blood expressing FOXP3 (A) or of CD3+ cells in gastric mucosa expressing FOXP3 (B) was compared between patients who were versus were not on a calcineurin inhibitor (CNI; tacrolimus or cyclosporine), mycophenolate mofetil (MMF), prednisone/methylprednisolone (Pred), or a combination of oral budesonide and beclomethasone dipropionate (BDP) at the time of biopsy.

The percent of CD4+ cells in blood expressing FOXP3 (A) or of CD3+ cells in gastric mucosa expressing FOXP3 (B) was compared between patients who were versus were not on a calcineurin inhibitor (CNI; tacrolimus or cyclosporine), mycophenolate mofetil (MMF), prednisone/methylprednisolone (Pred), or a combination of oral budesonide and beclomethasone dipropionate (BDP) at the time of biopsy.